Benzocycloheptabenzoquinolizines



United States Patent 3,361,751 315N216CYCLDHEPTABEIJZOQUENQLIZINES Leslie G. Humber, Bollard des Grmeaux, Quebec, and

Martin A. Davis, Montreal, Quebec, Canada, assignors to American Home Products Corporation, New York, N.Y., a corporation of Delaware No Drawing. Filed Nov. 30, 1%5, Ser. No. 510,678 1 Claim. (Cl. 269-289) This invention relates to new compounds containing a certain novel pentacyclic ring system, viz, the 1,2,3,4,6, 6a,ll,l2 octahydro 15b,H-benzo[4,5]cyclohepta[1,2,3- g,h]benzo[a]quinolizine ring system. These compounds may be represented generically by Formula I,

H or

The process for preparing the intermediates H, above, have been described in detail in our co-pending application, S.N. 484,440, filed Sept. 1, 1965. The process for preparing the novel compounds of this application, cnsists in the reaction of H with a methyl vinyl ketone derivative of Formula 111 wherein R has the same meaning as in Formula 1 above, in a suitable solvent such as, for example, methanol, ethanol, or isopropanol. A crystalline quaternary Schifis base derivative of Formula IV is obtained by this step, and this compound III.

0 "ice CH; U

is subsequently cyclized by dissolving in an aqueous medium and reacting with a basic reagent such as an alkali metal carbonate or hydroxide. The final products, I, are isolated by conventional extraction with a water immiscible solvent such as, for example, benzene or chloroform, and evaporation of the latter.

The compounds of this invention of Formula I possess useful pharmacological properties as trichomonicidal agents. Thus they are active against T. vaginalis and for this purpose the compounds of Formula I may be formulated, either as the free base or as a salt with a pharmacologically acceptable acid, as solutions, creams, lotions, or vaginal inserts with pharmacologically acceptable vehicles containing from 0.1 to 1.0 percent of the active ingredient.

The compounds of this invention also possess central nervous system regulatory activity.

The following examples will illustrate our invention.

EXAMPLE 1 3,8,9 trihydro 3a,H-benzo[6,7]cyclohepta[1,2,3-d,e]- isoquinoline hydrochloride (28.0 gm.) is dissolved in absolute ethanol (300 ml.) and cooled to 15. Freshly distilled methyl vinyl ketone (83 m1.) is added, the mixture refluxed for 6 hrs. then allowed to remain at room temperature for 15 hrs. Concentration of the reaction mixture yields crystals with a melting range of 185-2()6 C. They are dissolved in 500 ml. of 5% ethanol in water with heating, a few drops of 15% aqueous hydrochloric acid are added, the solution is filtered, cooled and made alkaline with 5% aqueous sodium carbonate. The resulting solution is extracted with chloroform to yield an oil. Crystallization from acetonitrile gives the title compound as a mixture of ISb-oz and 15b-[3 derivatives, recrystallized from absolute ethanol to M.P. 162-164 C. Its composition is confirmed by elementary analysis.

We claim:

1. 2-oxo-l,2,3,4,6,6a,11,12-octahydro 15b,H benze- [4, 5 1 cyclohepta[ 1,2,3-g,h]benzo [a] quinoliziue.

Van der Stelt et al., Receveil des Travaux Parp-Bas. vol. 85, pp. 1466- (1965).

ALEX MAZEL, Primary Examiner.

D. G. DAUS, Assistant Examiner. 

1. 2-OXO-1,2,3,4,6,6A,11,12-OCTAHYDRO-15B,H-BENZO(4,5)CYCLOHEPTA(1,2,3 -G,H)BENZO(A)QUINOLIZINE. 